Drugs / NI-071
last change May 2019 re-read 2 minutes ago

NI-071

Developed for
rheumatoid arthritis
Investigated by
Nichi-Iko Pharmaceutical Co., Ltd.

Trials 3 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01931189 Aug 2013 → Jan 2014 Nichi-Iko Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02990806 Jan 2017 → May 2019 rheumatoid arthritis Nichi-Iko Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 3 NCT01927263 Jul 2013 → Mar 2015 rheumatoid arthritis Nichi-Iko Pharmaceutical Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as NI-071 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931189
2

NCT01927263

NCT02990806

Route Intravenous “IV infusion.” NCT02990806